ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of photoreceptor loss and meaningful slowing of lesion growth measured by retinal pigment epithelium (RPE) loss in the fovea C1q blockade protected photoreceptor synapses and preserved retinal function in preclinical model, supporting the mechanistic understanding of ANX007 in preserving synaptic structures and visual function Initiation of Global Pivotal Phase 3 ARCHER II Trial vs.

ANX007在中央凹和非中央凹患者中表现出显着的，广泛的视力丧失保护作用，并且在低光环境中，ANX007保护了对视力重要的关键视网膜结构：显着减少了光感受器损失，并显着减缓了由视网膜色素上皮（RPE）测量的病变生长。中央凹C1q阻断保护的光感受器突触中的损失，并在临床前模型中保留了视网膜功能，支持了ANX007在保留突触结构和视觉功能方面的机制理解。全球关键3期ARCHER II试验vs。

Sham Control Expected mid-2024; Initiation of Pivotal Phase 3 Head-to-head ARROW Trial vs. SYFOVRE® Expected Second Half 2024 BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA.

假控制预计在2024年年中；启动关键的3期头对头ARROW试验与SYFOVRE®预计2024年下半年加利福尼亚州布里斯班，2024年5月7日（环球通讯社）--Annexon，Inc.（Nasdaq:ANNX），一家生物制药公司，为患有破坏性经典补体介导的身体，大脑和眼睛神经炎性疾病的人提供了新型治疗的晚期临床平台，今天介绍了地理萎缩（GA）2期ARCHER试验中ANX007的新分析，以及关于C1q在病原体消除光感受器突触中的作用及其在GA中C1q阻断的保护的新临床前数据。

ANX007 is a first-in-class, non-pegylated antigen-binding fragment (Fab) designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation, and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation by the European Medicines Agency.

ANX007是一种一流的非聚乙二醇化抗原结合片段（Fab），旨在通过玻璃体内制剂阻断C1q和眼部局部经典补体级联的激活，是治疗GA的第一个治疗候选药物，由欧洲药品管理局（European Medicines Agency）指定为优先药物（PRIME）。

The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. “We are pleased to present additional clinical data from the ARCHER trial tha.

这些数据在视觉与眼科研究协会（ARVO）2024年年会上发表。“我们很高兴提供ARCHER试验tha的其他临床数据。